

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-75) SATRALIZUMAB

PRONUNCIATION sat' ra liz' ue mab

THERAPEUTIC CLAIM Treatment of neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMO-SD)

CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human interleukin 6 receptor) (human-*Mus musculus* monoclonal SA237 heavy chain), disulfide with human-*Mus musculus* monoclonal SA237 light chain, dimer
2. Immunoglobulin G2-kappa, anti-(human interleukin-6 receptor subunit alpha (IL-6RA, membrane glycoprotein 80, CD126 antigen)); humanized monoclonal antibody: $\gamma 2$ heavy chain (1-443) [Humanized VH (*Homo sapiens* IGHV4-59*01 (76%) –(IGHD)-IGHJ4*01 (92%)) [9.7.12] (1-119) -*Homo sapiens* IGHG2*01 {CH1 C¹⁴>S(133), R¹⁶>K(135), E²⁰>G(139), S²¹>G(140); H C⁴>S(221); CH2 H³⁷>Q(266); CH3 R¹⁵>Q(353), Q⁷⁹>E(417), N⁹⁴>A(432), G¹⁰⁶>-(444), K¹⁰⁷>-(445)} (120-443)] (222-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (82%) – IGKJ2*01 (83%) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')] dimer (225-225":228-228")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLQESGPG	LVKPSSETLSL	TCAVSGHSIS	HDHAWSWVRQ	PPGEGLEWIG	50
FISYSGITNY	NPSLQGRVTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARSL	100
ARTTAMDYWG	EGTLVTVSSA	STKGPSVFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTVSW	NSGALTSQVH	TFFPAVLQSSG	LYSLSSVVTV	PSSNFGTQTY	200
TCNVDHKPSN	VVDVKTVERK	SCVECPPCPA	PPVAGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTFRV	300
VSVLTVVHQD	WLNQKEYKCK	VSNKGLPAPI	EKTIKTKGQ	PREPQVYTLP	350
PSQEEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPMLDSGD	400
SFFLYSKLTV	DKSRWQEGNV	FSCSVMHEAL	HAHYTQKSLS	LSP	443

Light chain

DIQMTQSPSS	LSASVGDSTV	ITCQASTDIS	SHLNWYQQK	GKAPPELLIYY	50'
GSHLLSGVPS	RFSGSGSGTD	FTFTISSLEA	EDAATYYCGQ	GNRLPYTFGQ	100'
GTKVEIERTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"	146-202	146"-202"
214'-222	214"-222"	225-225"	228-228"	259-319	259"-319"	365-423	365"-423"

Glycosylation sites (N)

Asn-295 Asn-295'

MOLECULAR FORMULA $C_{6340}H_{9776}N_{1684}O_{2022}S_{46}$ (peptide)

MOLECULAR WEIGHT 143.4 kDa (peptide)

TRADEMARK	None as yet
SPONSOR	Chugai Pharma
CODE DESIGNATIONS	SA237
<u>CAS</u> REGISTRY NUMBER	1535963-91-7
UNII	YB18NF020M
WHO NUMBER	10065

gbk